Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Tianjin Medical University China

Partnering Objectives
Xu Zhang
Professor 

TissUse GmbH Germany

TissUse is a Berlin, Germany-based, vibrant growth company who has developed a unique "Multi-Organ-Chip" platform that provides unprecdented preclinical insight on the systemic level using human tissue. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse's Multi-Organ-Chips provide a completely new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.
TissUse is additionally applying its platform and know-how to develop spin-off programs in a variety of tissue and organ repair areas starting with the cosmetic market of hair transplants.
Website:
https://www.tissuse.com/en/
Company Size (Fulltime employees)
11-50
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
Introduce TissUse HUMIMIC Multi-Organ-Chip technology & Initiate collaborations
Headquartner in China
No
Your Research Tool and Service name
HUMIMIC Multi-Organ-Chips, Neopapillae Hair Restoration, Technology Transfer, Multi-Organ-Chip Assay Development
Service Description
Multi-Organ-Chip A dynamic Multi-Organ-Chip platform has been designed to allow for easy integration of several organ-equivalents for advanced toxicity testing and cutting-edge disease modelling. Features: • Efficient human-like tissue nutrition • Flexible combination of different tissues • Long-term performance • Physiological shear stress applicable Rapid prototyping for specific customer needs in organ arrangement Neopapillae for Hair Restoration Hair transplantation is a procedure that is currently invasive and costly. TissUse has discovered a more efficient and less painful process. By isolating cells from the dermal papilla, the root of the hair follicle, it is possible to expand and culture those cells to form neopapillae. Each of these neopapilla has the potential to form a brand new hair follicle. Features: • more efficient compared to standard procedures • faster, more convenient and less painful • requires exceptional few biopsies and yields large number of hair inducing transplants Services: Technology Transfer and Multi-Organ-Chip Assay Development
Target client type
Pharma, Academia, Biotech
Mrs. Christine Schwenk
Busines Development Associate 
Functionality
Business Development

TomoWave Laboratories, Inc United States

TomoWave is developing a new medical imaging modality of optoacoustic tomography, using ultrasound generated by laser light to provide doctors the capability to solve numerous problems in cancer diagnostics, surgery and minimally invasive therapy.
Website:
tomowave.com
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Partnering Objectives
Please specify your partnering goal
Find strategic partner and investors
Headquartner in China
Yes
Medtech Category
Medtech Information 1
ARIA, Maestro, Symphony|Biomedical imaging system for molecular, functional and anatomical imaging|USA, CANADA, AUSTRALIA, EUROPE, JAPAN, KOREA, CHINA
Medtech Development Stage
Aleksey Krylov
CFO 
Functionality
Management

TOPSCIENCE China

Topscience is specializing in chemical and biological res earch product and service to meet the research needs of global customers. We offers over 80 types of compound liberties and a wide range of high-quality research chemical including inhibitors.，activator， natural compounds，peptides,inhibitory antibodies，and novel life-science kits, for laboratory and scientific use.Besifdes,virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

Website:
www.tsbiochem.com
Partnering Objectives
Headquartner in China
Yes
Summer Gao
sales specialist 

TOT BIOPHARM China

About TOT BIOPHARM International Company Limited
(HKG:1875)

TOT BIOPHARM is dedicated to developing and commercializing innovative cancer drugs and therapies, striving to build a leading brand of oncology treatments trusted by patients and their families as well as medical professionals.

The Group has in place three major integrated technology platforms:

Therapeutic Monoclonal Antibody and Antibody Drug Conjugates (ADCs) Technology Platform: it integrates research and development (R&D) and production capacities for antibody drugs and ADCs, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;

Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumor immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumor-targeted oncolytic virus products;

Innovative Drug Delivery Technology Platform: We have developed an innovative drug delivery system, including an advanced targeted liposome drug delivery system.

Using these platforms, the Group has studied and developed various anti-tumor drug series, and formed a high quality and comprehensive drug product chain. Currently, the Group has 12 drugs under research and development. On top of developing innovative proprietary drugs, TOT BIOPHARM also draws on its own industry value chain to build a complete industry chain platform that supports from R&D, clinical development to production and marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties in different stages along its industry value chain.

Website:
http://www.totbiopharm.com/
Company Size (Fulltime employees)
201-500
Year of foundation
2010
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Lily Lien
Director 

Trespa China Co., Ltd

Trespa is Top building material supplier and provide scientific surface solutions to laboratory environment. Our client includes Roche, BI, AZ, Pfizer, QiLu Pharma, Innocare , BASF etc
Website:
www. Trespa.com
Partnering Objectives
Headquartner in China
No
Emily Cao
Country Manager 

Tririver Capital China

an investment bank in shanghai
Website:
www.tririvercapital.com
Partnering Objectives
Headquartner in China
Yes
Li Pang
partner 

TusPark Holdings UK United Kingdom

TusPark UK is a science and technology service corporation with an investment arm as a venture capital and private equity group fund. TusPark UK has invested £250M+ in Cambridge since 2018 (e.g. the landmark joint venture with the Trinity College to develop and operate TusPark Cambridge Science Park), and its investment portfolio spans in the era of life science/healthcare, digital technologies (big data, AI and IoT, etc.), new material, and environmental & new energy, with a unique model of "Incubation + Investment + M&As".
Website:
www.tuspark.co.uk
Company Size (Fulltime employees)
5000+
Year of foundation
1994
Partnering Objectives
Please specify your partnering goal
look for investment opportunities and potential partner
Headquartner in China
Yes
Dr. Jerry Wu
Dr. Jerry Wu
LinkedIn logo Head of Investment 
Functionality
Investment

Usurpo Ltd. United Kingdom

Usurpo are a UK based specialist search firm focused on helping high-growth Life Sciences businesses hire outstanding executives worldwide. We have successfully run search campaigns in EMEA, ASIA PAC, India and the US.

We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.

We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:

- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders
Website:
www.usurpo.com
Company Size (Fulltime employees)
11-50
Year of foundation
2011
Partnering Objectives
Please specify your partnering goal
Network with international businesses to help them hire key leadership professionals in the US and Europe
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Your Research Tool and Service name
Executive Search
Service Description
Fast, cost effective and thorough executive search services to ensure you make the best international hires possible.
Target client type
Life Sciences companies looking to grow their presence in the US and Europe
Mr. Christopher Gibson
Head of Practice, Life Sciences 
Functionality
Management, Business Development, Human Resources

VITANLINK France

VITANLINK is a holding structure for business creation and project acceleration in deep tech fields such as AI, ICT and IoT applied to various sectors such as healthcare, finance, media and retail.
Within a competitive timeframe, start-ups and small and medium-sized businesses successfully move from seed to post-seed stages, from growth to scaling up to new markets
In partnership with family offices, advisory boutiques, regional accelerators and investment funds
Website:
Https://www.vitanlink.com
Year of foundation
2013
Partnering Objectives
Headquartner in China
No
Mrs. Tram TRINH
Mrs. Tram TRINH
CEO 
Functionality
Other